Gainers

• ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market session. The market value of their outstanding shares is at $2.4 million.
• Omeros (NASDAQ:OMER) stock moved upwards by 22.46% to $16.79. The company's market cap stands at $984.3 million. As per the news, the Q2 earnings report came out today.
• Bone Biologics (NASDAQ:BBLG) stock increased by 13.2% to $0.74. The company's market cap stands at $1.6 million.
• Biote (NASDAQ:BTMD) stock rose 9.85% to $1.56. The market value of their outstanding shares is at $46.7 million.
• Redhill Biopharma (NASDAQ:RDHL) stock moved upwards by 8.32% to $0.64. The company's market cap stands at $3.6 million.
• RenovoRx (NASDAQ:RNXT) stock moved upwards by 7.14% to $1.2. The company's market cap stands at $51.8 million. As per the press release, Q2 earnings came out today.

Losers

• Outlook Therapeutics (NASDAQ:OTLK) shares fell 16.2% to $0.92 during Wednesday's after-market session. The company's market cap stands at $211.3 million.
• Valion Bio (NASDAQ:VBIO) stock fell 14.61% to $0.19. The market value of their outstanding shares is at $1.2 million.
• Modular Medical (NASDAQ:MODD) stock decreased by 13.05% to $1.8. The company's market cap stands at $10.9 million.
• AngioDynamics (NASDAQ:ANGO) shares fell 11.37% to $13.96. The market value of their outstanding shares is at $650.9 million.
• Curis (NASDAQ:CRIS) stock decreased by 10.78% to $1.49. The market value of their outstanding shares is at $4.8 million.
• MaxCyte (NASDAQ:MXCT) stock fell 9.46% to $1.15. The market value of their outstanding shares is at $132.8 million. The company's, Q2 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.